The company's abbreviated new drug application (ANDA) for metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths is the generic equivalent for the corresponding strengths of the branded product Glucophage XR
sold in the US by Bristol-Myers Squibb.
Pharmaceutical company Merck Serono said in a statement that Glucophage XR
is an advanced formulation of the oral anti-diabetic agent Metformin.
Metformin Hydrochloride, a generic version of Bristol Myers Squibb's Glucophage XR
brand is mainly used to improve glycemic control in patients suffering from type-2 diabetes.
The product is the equivalent to Glucophage XR
, another Bristol-Myers product for treating type 2 diabetes.
Accupril - Agrylin - Axid - Biaxin - Celexa - Cipro - Difl ucan - Duragesic - Effexor - Flonase - Floxin/Occufl ox - Glucophage XR
- Glucotrol XL - Glucovance - Lotensin - Metaglip - Mobic - Monopril - Novantrone - Paraplatin - Paxil - Pravachol - Proscar - Retrovir - Rocephin - Romazicon - Tambocor - Ultram - Zaditor - Zestril/Prinivil - Zithromax - Zocor - Zofran - Zoloft
According to the company, Metformin Hydrochloride is a generic version of Bristol Myers Squibb s Glucophage XR
brand, which is used to enhance glycemic control in patients suffering from type-2 diabetes.
Metformin hydrochloride ER tablets USP 500mg and 750mg, which is ready for launch, is the generic equivalent of Bristol Myers Squibb Company (BMS) s Glucophage XR
extended-release tablets 500mg and 750mg respectively.
s Glucophage XR
Tablets, 750 mg, a product indicated for the treatment of type 2 diabetes.
Nasdaq:DEPO) reported results from an in vitro dissolution study that demonstrated statistically significantly different release rates between generic metformin extended release products compared to the currently marketed branded product, Glucophage XR
The product is the generic equivalent of Glucophage XR
(Bristol-Myers Squibb), an adjunct to diet and exercise for improving glycemic control in patients with type 2 diabetes.
However, the revenue growth of oral anti-diabetic agents continues to slow (+5% YoY) due to the patent expiry of leading brands such as Glucophage, Glucophage XR
and Glucovance and a slow down in prescription demand.
Bristol Meyers Squibb Company (NYSE:BMY) markets Glucophage XR
as an antidiabetic drug for the treatment of Type 2 (non-insulin dependent) diabetes.
The strong performance of the base business resulted in part from the fourth quarter debut of metformin HC1 extended-release tablets, the generic equivalent to Glucophage XR
Lubbert played an integral role in the success of the billion dollar diabetes franchise that included Glucophage, Glucovance and Glucophage XR
The product is the generic form of the latter company's Glucophage XR
, used in the treatment of Type 2 diabetes.